Chelsie Derman

FDA expands Ryaltris to younger children with seasonal allergic rhinitis, Palforzia discontinues, and HAE's oral pipeline widens with deucrictibant and sebetralstat.

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

In the OUTMATCH stage 2 randomized trial, omalizumab achieved greater intention-to-treat success than multiallergen oral immunotherapy.

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

Allergists explain what's settled about epinephrine nasal spray, what's not, and how to counsel patients before anaphylaxis guidelines catch up.

FDA expands RYALTRIS® approval to children aged 6 to 11 with seasonal allergic rhinitis, based on phase 3 trial data.

Arthur Caplan, PhD, and Dominic Sisti, PhD, revisit Jahi McMath's 5 years on a ventilator and what her case still says about how death is diagnosed.

New Phase 3 COMP006 data show durable MADRS improvement in treatment-resistant depression following two doses of synthetic psilocybin.

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Phase 3 RAPIDe-3 data show rapid, sustained relief of hereditary angioedema attacks; PDUFA date set for April 23, 2027.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

HAE gene editing, peanut patch trials, CSU sequencing, and EAC 2026 highlights in this allergy/immunology roundup for clinicians.

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

From FDA-approved at-home TMS and accelerated protocols to conversational AI matching group therapy outcomes, here are 5 psychiatry updates from May every clinician should know.

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

5 interviews in 5 minutes. Check out this HCPLive Five at ATS 2026 on late breaking data in sleep apnea, lung function recovery, PAH, lung disease, and COPD.

The FDA declined to approve Cingulate's once-daily ADHD therapy CTx-1301, citing CMC information requests with no clinical safety or efficacy concerns identified.

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

A study presented at the ATS 2026 found the New York City Housing Authority’s Mold Busters program was associated with nearly 2800 fewer annual asthma-related ED visits.

Transcranial magnetic stimulation for major depressive disorder is shifting toward accelerated (5x5 and SWIFT protocol) and at-home models (ProlivRx).

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

FDA expands lumateperone for relapse prevention in schizophrenia, White House boosts psychedelics research, and AI reshapes psychiatry care debates in April 2026.

FDA updates, phase 3 CRISPR data in HAE, and emerging food allergy prevention strategies defined allergy and immunology news in April 2026.

Phase 2 RAPIDe-1 trial shows an oral bradykinin B2 antagonist improves symptom relief and reduces rescue therapy use in hereditary angioedema attacks.

Phase 3 HAELO data show significant reductions in attack rates and treatment burden with a single-dose in vivo CRISPR therapy; BLA submission underway with FDA.

Twin phase 3 trials show triple therapy with budesonide–glycopyrronium–formoterol improves FEV1 and lowers severe exacerbation rates in patients with uncontrolled asthma on ICS–LABA